




Welcome and Introductions

Keiichi Fujiwara, MD, PhD



Speakers



Keiichi Fujiwara, MD, PhD
Saitama Medical University
International Medical Center,
Japan



**Domenica Lorusso, MD,
PhD**
Fondazione Policlinico
Gemelli IRCCS, Italy



Ana Oaknin, MD, PhD
Vall d'Hebron University
Hospital, Spain



**Leslie Randall, MD,
FACS, MAS**
Virginia Commonwealth
University, USA



Brian Slomovitz, MD
Mount Sinai Medical
Center, USA

Disclosures

Faculty

Keiichi Fujiwara, MD, PhD

Grant/Contract: AstraZeneca, MSD, Regeneron Pharmaceuticals
Consultant: Eisai Co. Ltd, MSD, Seagen and Genmab

Domenica Lorusso, MD, PhD

Honoraria: AstraZeneca, Clovis, Genmab, Immunogen, Merck, Roche, Tesaro/GSK, PharmaMar
Consulting or Advisory Role: AstraZeneca, Clovis Oncology, GSK, MSD, Immunogen, Genmab, Amgen, Seagen, PharmaMar, AstraZeneca, Merck Serono, Seagen, Genmab, Oncoinvent, Corcept Therapeutics, Sutro Biopharma
Speakers' Bureau: AstraZeneca, Clovis Oncology, GSK, MSD, PharmaMar
Research Funding: Clovis Oncology (Inst), Merck (Inst), PharmaMar (Inst), Tesaro/GSK (Inst)
Expert Testimony: Clovis Oncology
Travel, Accommodations, Expenses: AstraZeneca, Clovis Oncology, PharmaMar, Roche, Tesaro
Study funding, medical writing, and editorial support: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Ana Oaknin, MD, PhD

Consulting or Advisory Role: Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals, Eisai, Exelixis, EMD Serono, Roche, Genmab, GSK, ImmunoGen, ITEos, Merck Sharps & Dohme, Mersana Therapeutics, Novocure, OneXerna Therapeutics, Inc., PharmaMar, Regeneron, Shattuck Labs, Seagen, Sutro Biopharma
Travel, Accommodations, Expenses: AstraZeneca, PharmaMar, Roche
Research Funding: AbbVie (Inst), Advaxis Inc. (Inst), Aeterna Zentaris (Inst), Amgen (Inst), Aprea Therapeutics AB (Inst), BMS (Inst), Clovis Oncology (Inst), Eisai (Inst), Roche (Inst), Immunogen Inc (Inst), Merck, Sharp & Dohme (Inst), Millennium Pharmaceuticals (Inst), PharmaMar(Inst), Regeneron(Inst), Tesaro Inc. (Inst)

Leslie Randall, MD, FACS, MAS

Consultant: AstraZeneca, Clovis Oncology, GSK, Immunogen, Seagen

Brian Slomovitz, MD


Consultant: AbbVie, AstraZeneca, Clovis Oncology, GSK, Genentech, Merck, Myriad Genetic

Incorporating Breakthrough Cervical Cancer Data into Practice

12:40 – 12:50	Welcome and Introductions	Keiichi Fujiwara, MD, PhD
12:50 – 13:10	Decoding the Latest Developments in Locally Advanced and First-Line Recurrent Cervical Cancer	Domenica Lorusso, MD, PhD Keiichi Fujiwara, MD, PhD
13:10- 13:30	The Changing Landscape of Second-Line Therapies for Recurrent Cervical Cancer	Leslie Randall, MD, FACS, MAS Ana Oaknin, MD, PhD
13:30 – 13:50	Have New Substances Changed How Patients Are or Will Be Treated? Real-World Experiences	Brian Slomovitz, MD
13:50 – 14:05	Fireside Chat: Audience and Panel Facilitated Discussion	All Faculty
14:05 – 14:10	Closing Remarks	Keiichi Fujiwara, MD, PhD

Take Part In The Discussion!

SCAN THE
UNIQUE QR CODE
TO PARTICIPATE



*Please submit your name to participate in the
interactive polls*